Last reviewed · How we verify
Cyproviron (CYPROTERONE ACETATE)
Cyproterone acetate works by binding to the progesterone receptor, thereby blocking the effects of androgens and estrogens on the body.
Cyproterone acetate is a synthetic steroid and a member of the cyproterone class of drugs. It primarily targets the progesterone receptor, which plays a crucial role in the regulation of the menstrual cycle and fertility. As a small molecule, cyproterone acetate is used to treat conditions such as acne, hirsutism, and precocious puberty in children. However, its commercial status and FDA approval are unknown. Further research is needed to determine its efficacy and safety in various clinical settings.
At a glance
| Generic name | CYPROTERONE ACETATE |
|---|---|
| Drug class | cyproterone |
| Target | Androgen receptor, Glucocorticoid receptor, Mu-type opioid receptor |
| Modality | Small molecule |
| Therapeutic area | Pain |
| Phase | discontinued |
Mechanism of action
Imagine your body has locks on the doors of cells that control hormones. Cyproterone acetate is a key that fits into these locks, preventing other hormones from entering and causing problems. This helps to regulate the balance of hormones in the body, particularly in conditions where there's an overproduction of androgens or estrogens.
Approved indications
Common side effects
- Meningioma
- Hepatitis fulminant
- Prosopagnosia
- Frontotemporal dementia
Key clinical trials
- MEdical Versus SUrgical Treatments of Rectal Endometriosis (PHASE3)
- Functional Study of the Hypothalamus in Magnetic Resonance Imaging (MRI) in Polycystic Ovary Syndrome (PCOS) (NA)
- Gender-Affirming Hormone Therapy and Its Impact on Myocardial Mass and Cardiac Function, Heart, Liver and Pancreatic Fat Content
- Cardiovascular Health of Transgender Individuals During the Gender-affirming Pathway
- Comparing the Effects of Sublingual Estradiol Treatment Versus Oral Estradiol With Cyproterone Acetate (CPA) Treatment on The Coagulation System in Transgender Women: A Prospective, Controlled Cohort Study (NA)
- GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients (PHASE2,PHASE3)
- Clinical Study on the Safety and Efficacy of Human Amniotic Mesenchymal Stem Cells in the Treatment of Premature Ovarian Insufficiency (PHASE1,PHASE2)
- The Progression From Dysmenorrhoea to Chronic Pelvic Pain
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cyproviron CI brief — competitive landscape report
- Cyproviron updates RSS · CI watch RSS